SCHEMBL4285256

SCHEMBL4285256

CC(=O)n1ncc2cc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)ccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 12/20 0.57
PRKACA P17612 8/20 0.57
CDK2 P24941 8/20 0.57
GSK3B P49841 8/20 0.57
CLK4 Q9HAZ1 7/20 0.57
MAP4K4 O95819 7/20 0.57
MKNK2 Q9HBH9 6/20 0.57
PIM1 P11309 4/20 0.57
HIPK2 Q9H2X6 3/20 0.57
ROCK2 O75116 7/20 0.48
PRKX P51817 6/20 0.48
JAK3 P52333 6/20 0.48
CDK5 Q00535 6/20 0.48
MAP4K2 Q12851 6/20 0.48
DYRK1A Q13627 6/20 0.48
PKN2 Q16513 6/20 0.48
MAP4K5 Q9Y4K4 6/20 0.48
GSK3A P49840 6/20 0.48
AURKA O14965 5/20 0.48
PRKD3 O94806 5/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27788240 0.90 CDC7 (0.55) CDC7PRKACACDK2GSK3BCLK4
SCHEMBL4291536 0.89 CDC7 (0.54) CDC7PRKACACDK2GSK3BCLK4
SCHEMBL4289485 0.89 CLK4 (0.48) CDC7PRKACACDK2GSK3BCLK4
SCHEMBL27788225 0.85 CLK4 (0.44) CDC7PRKACACDK2GSK3BCLK4
SCHEMBL3669460 0.84 CLK4 (0.49) CDC7PRKACACDK2GSK3BCLK4
SCHEMBL3664505 0.82 CDC7 (0.41) CDC7PRKACACDK2GSK3BCLK4
SCHEMBL3669967 0.73 CDC7 (0.62) CDC7CDK2GSK3BCLK4ROCK2
SCHEMBL2898117 0.73 IDO1 (0.65) CDC7PRKACACDK2GSK3BCLK4
SCHEMBL3667859 0.73 CDC7 (1.00) CDC7PRKACACDK2GSK3BCLK4
SCHEMBL3632690 0.72 CDC7 (0.58) CDC7PRKACACDK2GSK3BCLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885PRKACA 178/4885CDK2 65/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885PRKACA 178/4885CDK2 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.